Lyell Immunopharma, Inc.
Income Statement
| Line Item | Aug 2025 | Jun 2025 | May 2025 | Mar 2025 | Mar 2025 | Dec 2024 | Nov 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $8.0K | — | $7.0K | — | — | — | $34.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $34.9M | — | $43.4M | — | — | — | $39.5M |
| SG&A Expense | — | $9.8M | — | $14.0M | — | — | — | $11.8M |
| Operating Income | — | $-47.1M | — | $-57.4M | — | — | — | $-50.5M |
| Operating Margin | — | -589,250.0% | — | -819,528.6% | — | — | — | -148,544.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-42.7M | — | $-52.2M | — | — | — | $-44.6M |
| Net Margin | — | -533,550.0% | — | -745,642.9% | — | — | — | -131,126.5% |
| EPS (Basic) | — | $-2.89 | — | $-3.54 | — | — | — | $-3.48 |
| EPS (Diluted) | — | $-2.89 | — | $-3.54 | — | — | — | $-3.48 |
| Shares Outstanding (Basic) | 19.2M | 14.8M | 295.3M | 14.8M | 295.2M | 14.7M | 279.2M | 12.8M |
| Shares Outstanding (Diluted) | 19.2M | 14.8M | 295.3M | 14.8M | 295.2M | 14.7M | 279.2M | 12.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |